Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings
Clinical and scientific data presentations in support of Gvoke® (glucagon) injection, Recorlev® (levoketoconazole), and the investigational XP-8121 program underscore Xeris's leadership in endocrinology, including the treatments for Severe Hypoglycemia, Cushing's Syndrome, and Hypothyroidism
CHICAGO, October 15, 2026--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading, endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines, today announced clinical and scientific data presentations from its commercial portfolio and development pipeline at three scientific meetings this fall: Breakthrough T1D Clinical & Research Congress (CRC), the 21st Annual Cardiometabolic Health Congress (CMHC), and the American Thyroid Association (ATA) Annual Meeting.
"These presentations reflect the breadth and depth of our scientific work and collaborations across endocrinology, as well as our commitment to advancing care at every stage, from established therapies to emerging treatment approaches," said Anh Nguyen, MD, Chief Medical Officer of Xeris Biopharma. "By sharing real-world experience with Recorlev and new research on Gvoke, we continue to build the evidence supporting therapies patients rely on today. At the same time, our TriNetX analysis expands our understanding of real-world biochemical control among patients with hypothyroidism treated with oral levothyroxine."
Presentation Highlights
Severe Hypoglycemia – Gvoke at the 2026 Breakthrough T1D Clinical & Research Congress
New real-world data examines the gap between HCP awareness of American Diabetes Association standard of care treatment guidelines for prescribing ready-to-use glucagon, when compared to actual prescribing practices. Data underscores the unmet clinical unmet need and ongoing opportunity to increase adoption of ready-to-use glucagon products.
Hypercortisolism in Cushing's Syndrome and associated cardiometabolic comorbidities – Recorlev at the 2026 Cardiometabolic Health Congress
A compelling case study demonstrates normalization of cortisol following treatment with levoketoconazole, accompanied by meaningful improvements in multiple cardiometabolic parameters, in a patient with uncontrolled Type 2 diabetes, hypertension, and multiple comorbidities. This case study highlights the important role of cortisol normalization in cardiometabolic health.
Hypothyroidism – Characterization of a real-world hypothyroid population using linked levothyroxine treatment and TSH data at the 2026 American Thyroid Association Annual Meeting
First public presentation of a real-world analysis using linked levothyroxine treatment records and TSH laboratory data to characterize patients with hypothyroidism and explore approaches for longitudinal assessment.